Literature DB >> 31329538

Retinal vasculitis the first clue in the diagnosis of progressive hemifacial atrophy.

Atefeh Vafa1, Ofelya Gevorgyan2, Debalina De1, Sobia Hassan2.   

Abstract

Retinal vasculitis is a sight-threatening condition that can occur as an isolated ocular disorder or in association with a number of systemic diseases. Parry-Romberg syndrome, also known as progressive hemifacial atrophy (PHA), is a rare disorder of unknown etiology characterized by unilateral facial atrophy and is associated with multiple ophthalmologic and neurologic manifestations. Here we report the case of a 17-year-old man with no prior diagnosis of PHA, who presented with a sudden onset of floaters and decreased vision in the right eye; he was found to have retinal vasculitis and uveitis in the right eye. Routine workup did not reveal the cause of retinal vasculitis. However, thorough physical examination demonstrated features of PHA overlapping with linear scleroderma en coup de sabre. The patient was started on treatment with systemic steroids with a later addition of methotrexate; he responded to treatment with considerable improvement in his symptoms and ophthalmologic examination.

Entities:  

Year:  2019        PMID: 31329538      PMCID: PMC6812904          DOI: 10.5152/eurjrheum.2019.18100

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  10 in total

Review 1.  A review of Parry-Romberg syndrome.

Authors:  Jessica El-Kehdy; Ossama Abbas; Nelly Rubeiz
Journal:  J Am Acad Dermatol       Date:  2012-03-07       Impact factor: 11.527

2.  The Parry Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre. Mistaken diagnosis or overlapping conditions?

Authors:  T J Lehman
Journal:  J Rheumatol       Date:  1992-06       Impact factor: 4.666

Review 3.  [Ocular manifestations of primary systemic vasculitis].

Authors:  Rosa Elda Barbosa-Cobos; Claudia Recillas-Gispert; Lourdes Arellanes-García
Journal:  Reumatol Clin       Date:  2011-11-25

Review 4.  Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis.

Authors:  Esperanza Pato; Santiago Muñoz-Fernández; Félix Francisco; Miguel A Abad; Jesús Maese; Ana Ortiz; Loreto Carmona
Journal:  Semin Arthritis Rheum       Date:  2010-07-24       Impact factor: 5.532

5.  Parry-Romberg syndrome: follow-up imaging during suppressive therapy.

Authors:  H Goldberg-Stern; T deGrauw; M Passo; W S Ball
Journal:  Neuroradiology       Date:  1997-12       Impact factor: 2.804

6.  Autoantibodies in Parry-Romberg syndrome: a serologic study of 14 patients.

Authors:  I Garcia-de la Torre; J Castello-Sendra; T Esgleyes-Ribot; G Martinez-Bonilla; J Guerrerosantos; M J Fritzler
Journal:  J Rheumatol       Date:  1995-01       Impact factor: 4.666

7.  Parry-Romberg syndrome: a global survey of 205 patients using the Internet.

Authors:  Jon Stone
Journal:  Neurology       Date:  2003-09-09       Impact factor: 9.910

8.  Parry-Romberg syndrome: facial atrophy and its relationship with other regions of the body.

Authors:  Ahmet Duymaz; Furkan Erol Karabekmez; Mustafa Keskin; Zekeriya Tosun
Journal:  Ann Plast Surg       Date:  2009-10       Impact factor: 1.539

9.  Neurological Manifestations in Parry-Romberg Syndrome: 2 Case Reports.

Authors:  Justine Vix; Stéphane Mathis; Mathieu Lacoste; Rémy Guillevin; Jean-Philippe Neau
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

10.  Parry Romberg syndrome with a wide range of ocular manifestations: a case report.

Authors:  Antonio Maria Fea; Vittoria Aragno; Cristina Briamonte; Mauro Franzone; Davide Putignano; Federico Maria Grignolo
Journal:  BMC Ophthalmol       Date:  2015-09-05       Impact factor: 2.209

  10 in total
  1 in total

1.  Occlusive retinal vasculitis associated with systemic sclerosis and antiphospholipid antibodies.

Authors:  Caleb C Ng; Sandip Suresh; James T Rosenbaum; H Richard McDonald; Emmett T Cunningham
Journal:  Am J Ophthalmol Case Rep       Date:  2021-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.